Last update Aug. 20, 2022
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
17α,21-Dihydroxy-16β-methylpregna-1,4-diene-3,11,20-trione is Meprednisone in Chemical name.
Is written in other languages:17α,21-Dihydroxy-16β-methylpregna-1,4-diene-3,11,20-trione is also known as
17α,21-Dihydroxy-16β-methylpregna-1,4-diene-3,11,20-trione belongs to this group or family:
Main tradenames from several countries containing 17α,21-Dihydroxy-16β-methylpregna-1,4-diene-3,11,20-trione in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 80 | % |
Molecular weight | 373 | daltons |
Protein Binding | 80 - 90 | % |
pKa | 12.44 | - |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A corticosteroid with a chemical structure and clinical effects similar to prednisone. It is a metabolite of methylprednisolone (Bago 2006). It has a predominantly glucocorticoidal action with little mineralocorticoidal action. Oral administration or injectable every 6 to 24 hours.
Since the last update date we have not found published data on its excretion in breastmilk.
Its high percentage of plasmatic protein binding makes it unlikely it will transfer to milk in significant amounts.
Other corticosteroids with a similar structure and actions are excreted in milk in insignificant amounts and are considered compatible with breastfeeding.
Corticosteroids are commonly used in pediatrics and lack side effects when they are used alone or in short-term treatments.
Meprednisone is marketed in few countries, It has very few bibliographical references and its pharmacokinetics are little known. (Gador 2011, Bago 2006)
Until there is more published data about this drug in relation to breastfeeding, safer alternatives may be preferred, especially during the neonatal period and in the case of prematurity.